Quest Diagnostics (DGX) has been earning attention in the biotech market due to a series of positive reports and indicators. The company's stock performance has been bolstered by several prominent happenings, including its release of the 2024 Corporate Responsibility Report, and upcoming Q2 2025 Earnings Report. Its solid financial results have led to the stock being classified as a '"Safe Haven
Quest Diagnostics DGX News Analytics from Mon, 26 Aug 2024 07:00:00 GMT to Thu, 03 Jul 2025 12:37:00 GMT -
Rating 8
- Innovation 7
- Rumor -3